ELR-CXC chemokine antagonism in neutrophilic inflammation

点击翻译按钮获取中文摘要

While we understand the basic biology of numerous individual inflammatory molecules in the body, we have yet to generate a reasoned overview of how they interact with each other. Anecdotal evidence suggests that there exists a much greater interdependence of these functions than previously appreciated. We have developed a new anti-inflammatory drug, called G31P, that blocks an entire class of inflammatory molecules, and so is highly effective as an anti-inflammatory drug. In fact, it is much more effective than we would have predicted, so we wish to know exactly how it works in blocking the activities of other classes of inflammatory molecules. We have some evidence that is also blocks processes not traditionally thought of as inflammatory (e.g., the spread of cancer cells through the body). We will use a combination of test tube and live animals studies with lab animals, pre-clinical studies with experimental pigs, and clinical studies with dogs with melanoma tumours to investigate these issues. Overall, these studies are designed allow us to develop G31P for veterinary uses as diverse as pneumonia, arthritis, and cancer.